CN102271763A - 抑制hdac2以促进记忆 - Google Patents

抑制hdac2以促进记忆 Download PDF

Info

Publication number
CN102271763A
CN102271763A CN2009801532239A CN200980153223A CN102271763A CN 102271763 A CN102271763 A CN 102271763A CN 2009801532239 A CN2009801532239 A CN 2009801532239A CN 200980153223 A CN200980153223 A CN 200980153223A CN 102271763 A CN102271763 A CN 102271763A
Authority
CN
China
Prior art keywords
hdac2
inhibitor
memory
formula
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801532239A
Other languages
English (en)
Chinese (zh)
Inventor
L-H·蔡
A·菲驰尔
S·哈盖蒂
W·唐
S·L·赤瑞贝尔
E·霍森
F·沃格尼尔
M·P·摩耶尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Massachusetts Institute of Technology
Harvard University
Original Assignee
General Hospital Corp
Massachusetts Institute of Technology
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Massachusetts Institute of Technology, Harvard University filed Critical General Hospital Corp
Publication of CN102271763A publication Critical patent/CN102271763A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Storage Device Security (AREA)
  • Techniques For Improving Reliability Of Storages (AREA)
CN2009801532239A 2008-12-03 2009-12-02 抑制hdac2以促进记忆 Pending CN102271763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11969808P 2008-12-03 2008-12-03
US61/119,698 2008-12-03
PCT/US2009/006355 WO2010065117A1 (en) 2008-12-03 2009-12-02 Inhibition of hdac2 to promote memory

Publications (1)

Publication Number Publication Date
CN102271763A true CN102271763A (zh) 2011-12-07

Family

ID=42233521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801532239A Pending CN102271763A (zh) 2008-12-03 2009-12-02 抑制hdac2以促进记忆

Country Status (8)

Country Link
US (1) US20120101147A1 (https=)
EP (1) EP2367599A4 (https=)
JP (1) JP2012510512A (https=)
CN (1) CN102271763A (https=)
AU (1) AU2009322958B2 (https=)
CA (1) CA2745073A1 (https=)
NZ (1) NZ593447A (https=)
WO (1) WO2010065117A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163741A (zh) * 2013-04-29 2015-12-16 淑明女子大学校产学协力团 包含dna甲基化抑制剂的常染色体显性多囊肾改善或治疗用药学组合物
CN107849061A (zh) * 2015-06-08 2018-03-27 加利福尼亚大学董事会 H3K9me3调控用于增强认知功能的用途
CN110951738A (zh) * 2019-12-23 2020-04-03 华南农业大学 猪hdac2基因的表达抑制剂及其应用
CN110997002A (zh) * 2017-07-13 2020-04-10 麻省理工学院 靶向hdac2-sp3复合体以增强突触功能
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
CN115192714A (zh) * 2022-07-08 2022-10-18 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
CN116270932A (zh) * 2021-12-13 2023-06-23 南京大学 一种具有治疗脑损伤疾病的安宫牛黄丸小rna组合及其应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
WO2011053876A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2012016081A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Method and therapeutic for the treatment and regulation of memory formation
CN102477001B (zh) * 2010-11-29 2015-07-15 江苏先声药物研究有限公司 一种苯甲酰胺类组蛋白去乙酰化酶抑制剂
EP2701699B1 (en) 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013016193A2 (en) 2011-07-22 2013-01-31 Massachusetts Istitute Of Technology Activators of class i histone deacetlyases (hdacs) and uses thereof
US20130028956A1 (en) * 2011-07-29 2013-01-31 Andre Fischer Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore
WO2013096744A1 (en) * 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014018913A2 (en) * 2012-07-27 2014-01-30 University Of Connecticut Santacruzamate a compositions and analogs and methods of use
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
WO2014046871A1 (en) * 2012-09-04 2014-03-27 Massachusetts Institute Of Technology The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
HK1214587A1 (en) 2012-12-28 2016-07-29 Nippon Zoki Pharmaceutical Co., Ltd. Cinnamamide derivative
EP2801569A1 (en) 2013-05-09 2014-11-12 Ikerchem, S.L. Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings
MX2016006633A (es) * 2013-11-24 2016-12-02 Univ Taipei Medical Uso de hidroxamatos de indolilo e indolinilo para tratar trastornos neurodegenerativos o deficiencias cognitivas.
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
WO2016134271A1 (en) * 2015-02-19 2016-08-25 Massachusetts Institute Of Technology Systems and methods for selective memory enhancement and/or disruption
WO2017039726A1 (en) 2015-08-28 2017-03-09 Uwm Research Foundation, Inc. Novel hdac inhibitors and methods of treatment using the same
WO2019014656A1 (en) 2017-07-14 2019-01-17 Han Si Ping METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
EP3665281A4 (en) * 2017-08-10 2021-05-05 City of Hope CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY
AU2018331278A1 (en) 2017-09-18 2020-03-26 Massachusetts Institute Of Technology Cyclin-dependent kinase 5 (CDK5) inhibitory peptides
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
WO2019235501A1 (ja) * 2018-06-06 2019-12-12 塩野義製薬株式会社 ヒストン脱アセチル化酵素阻害剤
CN113166750B (zh) 2018-08-10 2025-02-18 希望之城 可编程的条件性sirna及其用途
JP7522726B2 (ja) * 2019-03-28 2024-07-25 株式会社カネカ ピロールイミダゾール（ポリ）アミドの製造方法
EP3982968A4 (en) * 2019-06-13 2023-07-05 Dana-Farber Cancer Institute, Inc. DEVELOPMENT OF HDAC3 CATALYTIC INHIBITOR AND USES THEREOF
WO2021117759A1 (ja) 2019-12-10 2021-06-17 塩野義製薬株式会社 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤
IL313081A (en) 2021-12-03 2024-07-01 Tango Therapeutics Inc New HDAC inhibitors and their medical use
WO2024245060A1 (zh) * 2023-06-02 2024-12-05 苏州浦合医药科技有限公司 HDAC1-CoREST高选择性抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054647A1 (en) * 2002-12-27 2005-03-10 Detlev Schuppan New pharmaceutical combination
TW200424174A (en) * 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008086452A2 (en) * 2007-01-10 2008-07-17 Columbia University Treatment and prevention of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US20070078083A1 (en) * 2005-09-07 2007-04-05 Braincells, Inc. MODULATION OF NEUORGENESIS BY HDac INHIBITION

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163741A (zh) * 2013-04-29 2015-12-16 淑明女子大学校产学协力团 包含dna甲基化抑制剂的常染色体显性多囊肾改善或治疗用药学组合物
CN105163741B (zh) * 2013-04-29 2018-01-02 淑明女子大学校产学协力团 包含dna甲基化抑制剂的常染色体显性多囊肾改善或治疗用药学组合物
CN107849061A (zh) * 2015-06-08 2018-03-27 加利福尼亚大学董事会 H3K9me3调控用于增强认知功能的用途
CN107849061B (zh) * 2015-06-08 2021-05-14 加利福尼亚大学董事会 H3K9me3调控用于增强认知功能的用途
CN110997002A (zh) * 2017-07-13 2020-04-10 麻省理工学院 靶向hdac2-sp3复合体以增强突触功能
CN110951738A (zh) * 2019-12-23 2020-04-03 华南农业大学 猪hdac2基因的表达抑制剂及其应用
CN110951738B (zh) * 2019-12-23 2021-10-15 华南农业大学 猪hdac2基因的表达抑制剂及其应用
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
CN116270932A (zh) * 2021-12-13 2023-06-23 南京大学 一种具有治疗脑损伤疾病的安宫牛黄丸小rna组合及其应用
CN116270932B (zh) * 2021-12-13 2024-08-23 南京大学 一种具有治疗脑损伤疾病的安宫牛黄丸小rna组合及其应用
CN115192714A (zh) * 2022-07-08 2022-10-18 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途

Also Published As

Publication number Publication date
WO2010065117A1 (en) 2010-06-10
EP2367599A1 (en) 2011-09-28
AU2009322958B2 (en) 2015-03-19
NZ593447A (en) 2012-12-21
JP2012510512A (ja) 2012-05-10
US20120101147A1 (en) 2012-04-26
EP2367599A4 (en) 2012-08-08
AU2009322958A1 (en) 2011-07-07
CA2745073A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
AU2009322958B2 (en) Inhibition of HDAC2 to promote memory
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
Chaudhury et al. The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies
TWI813078B (zh) sGC刺激劑
US20080188524A1 (en) Methods of treating pain
JP6381523B2 (ja) Ｐｉ−３キナーゼ阻害剤の投与レジメン
CN101360422A (zh) 致癌Ras特异性细胞毒化合物及其使用方法
MX2008016083A (es) Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3.
JP2020504721A (ja) イブジラストを使用した多形膠芽腫の治療方法
JP2009534415A (ja) ニューロトロフィン発現に対するａｍｐａ受容体モジュレーターの作用の薬理学的制御
KR20110070919A (ko) 스핑고신-１-포스페이트 수용체 길항제 및 항마이크로튜블 제제의 상승적 조합물
ES2741012T3 (es) Derivados utilizados en el tratamiento de atrofia muscular
ES2358931T3 (es) Uso de un inhibidor de quinasa p38 para el tratamiento de trastornos psiquiatricos.
HK1211926A1 (en) The inhibitor of casein kinase 1 delta and casein kinase 1 epsilon
Costa et al. Epigenetic targets in GABAergic neurons to treat schizophrenia
MXPA04009496A (es) Remedio para glioblastoma.
CN100588395C (zh) 含有环氧化酶-2抑制剂的止痛和抗炎药物
WO2025157286A1 (zh) 包含prmt5抑制剂和mat2a抑制剂的药物组合物
AU2018313990A1 (en) Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease
ES3012548T3 (en) Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN121177493A (zh) 一种药物组合及其应用
US20170105952A1 (en) Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
JP2002524507A (ja) 新規組成物
KR20010099647A (ko) 신규 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20111207

RJ01 Rejection of invention patent application after publication